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Due to difficulties in direct diagnosis ofMycobacterium tuberculosis infection where site-spe-
cific specimens are not available, indirect methods of testing for infection are required. M.
tuberculosis early secreted antigen target-6 (ESAT6) induced IFN-c responses are specific, but
do not differentiate between latent and active TB. The use of adjunct biomarkers for TB
diagnosis has been proposed, such as the chemokines: CXCL9, CXCL10 and CCL2.
ESAT6-induced IFN-c CXCL9, CXCL10 and CCL2 was measured in whole blood cell super-
natants of patients with pulmonary tuberculosis (PTB, n = 36) and extrapulmonary TB (ETB,
n = 31) and compared with healthy endemic controls (EC, n = 33).
ESAT6-induced IFN-c responses were positive in 32% of TB cases as comparedwith 15% of
EC cases (p = 0.048). ESAT6-induced CXCL9 responses were positive in 42% of TB cases and
15% of EC cases (p = 0.006). ESAT6-induced-CXCL10 and -CCL2 responses did not discrimi-
nate between TB and EC groups. Measurement of IFN-c or CXCL9 together diagnosed TB
(53%) cases and was significant as compared with EC (p = 0.014) cases. IFN-c and CXCL10
together did not increase the number of TB cases diagnosed.
Within TB groups, ESAT6-IFN-c/CXCL9-based detection increased to 53% in PTB (p = 0.031)
and 54% in ETB (p = 0.021), with comparable diagnosis in less severe extrapulmonary TB (L-
ETB, 55%) and severe disseminated extrapulmonary TB (D-ETB, 50%). Given that 47% of TB
cases remained undetected, this study shown that ESAT6-induced IFNc and CXCL9 can
support diagnosis, but must be supported by clinical correlation and other relevant
investigations.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction detection ofMycobacterium tuberculosis, especially in paucibac-Tuberculosis (TB) causes almost 2 million deaths annually [1].
Diagnosis of TB remains a challenge owing to the difficulty in-African Society for Myco
ent of Pathology and Mic
4930051x4511; fax: +92 21
Hasan).illary disease, when there are limited numbers of bacilli in
clinical specimens, or access to site-specific specimens is dif-
ficult, such as in cases of extrapulmonary TB (ETB). Indirectbacteriology. Published by Elsevier Ltd. All rights reserved.
robiology, Aga Khan University Hospital, P.O. Box 3500, Stadium
34934294.
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methods of detection, and a number of immune biomarkers
have been identified to be potentially useful as diagnostic,
predictive and prognostic markers of disease [2]. Ideally, the
biomarker should be able to differentiate between healthy
individuals and those with active disease. The biomarkers
should also be useful in an endemic setting where there are
high transmission rates and increased exposure to environ-
mental mycobacteria. Initially, it was thought that inter-
feron-gamma (IFN-c) responses to M. tuberculosis specific
antigens would be useful for predicting active TB in individu-
als. IFN-c responses to the region of difference (RD)-1, recom-
binant antigen early secreted and T cell activated (ESAT)-6
and culture filtrate protein (CFP)-10 have been shown to be
effective in detection of infected individuals [3–5]. Commer-
cial IFN-c response assays (IGRA) based on ESAT-6 and CFP-
10 are more specific for detecting M. tuberculosis infection [4]
and are not affected by the bacille Calmette–Guerin (BCG) vac-
cination of the host, however, they do not discriminate be-
tween latent and active infection [6]. Hence, IGRAs are not
recommended for diagnosis of TB. Also, these assays are less
effective in cases where T-cell responses may be compro-
mised such as in immune-compromised individuals with hu-
man immune deficiency virus (HIV) infection [7], owing to
increased exposure to environmental mycobacteria [8] and
in pediatric TB [9].
In the absence of effective Th1 cell immunity, it may be
useful to have biomarkers of innate immune responses. An
effective granulomatous response is essential for the restric-
tion of infection with M. tuberculosis, and it is the appropriate
activation of leucocytes via their chemokine receptors that
leads to appropriate migration and localization [10]. A num-
ber of chemokines are activated by IFN-c, such as CXCL9,
CXCL10, CXCL11 and CXCL12 [11]. CXCL9 levels are increased
in patients with TB [12]. CXCL9 has been shown to be a mar-
ker for antigen-specific IFN-c production and IFN-c secreting
cells [13]. The IFN-c inducible protein 10 (IP10 or CXCL10) is
a marker of T-helper-1 (Th1) cells. It directs the migration
and stimulates the adhesion of activated T-cells and natural
killer cells by binding CXCR3, a G-protein coupled receptor.
CXCL10 plays an important role in recruiting activated T cells
into sites with tissue inflammation [11]. Recent reports have
indicated the utility of CXCL10 for diagnosis of TB in latent
infection [14] and in children with TB [15]. CCL2, or monocyte
chemoattractant protein, is the most potent activator of
monocytes and is responsible for recruitment of leucocytes
through the CCR2 and CCR5 receptors to the site of infection
[11]. CCL2 is activated by TNFa (tumor necrosis factor alpha)
and plays an important role in protection against tuberculosis
in the murine model [16]. CCL2 is differentially expressed in
pulmonary and extrapulmonary tuberculosis [17]. CCL2 has
also been suggested to be a biomarker for TB [18]. Both
CXCL10 and CCL2 have been suggested to be useful for dis-
crimination between individuals with and without tuberculo-
sis infections [18,19].
Tuberculosis predominantly manifests itself as an
infection of the lung parenchyma, but extrapulmonary forms
of the disease remain common and can comprise up to 35%
of cases [20]. As cytokine and chemokine responses to
Mycobacterium and to mycobacterial antigens, ESAT-6 andCFP-10 differ in patients with pulmonary (PTB) or extrapulmo-
nary (EPTB) disease [19]. The utility of CXCL9, CXCL10 and
CCL2 has been addressed as additional biomarkers in con-
junction with ESAT6-induced IFN-c responses to diagnose
TB in a highly endemic, BCG-vaccination population.Materials and methods
Ethics statement
The study was approved by the Ethical Review Committee of
The Aga Khan University and DOW University of Healthy Sci-
ences (DUHS), Karachi, Pakistan. All patients provided written
informed consent for the collection of samples and subse-
quent analysis.
Subject selection
Seventy seven patients were recruited from the Aga Khan
University Hospital and Medical College (AKUH), OJHA Insti-
tute of Chest Disease, Dow University of Health Sciences
(DUHS) and Indus Hospital, Karachi. Patients were newly
diagnosed or had taken less than 7 days of anti-tuberculous
therapy (ATT). Patients with significant co-morbid conditions,
including diabetes mellitus, chronic renal failure, and chronic
liver disease, and patients on high-dose corticosteroid ther-
apy were excluded to ensure relatively unmodulated immu-
nological parameters. All patients were HIV negative.
Patients with pulmonary TB (PTB, n = 36) were diagnosed
by clinical examination, chest X-ray, sputum acid fast bacillus
(AFB) Ziehl–Neelsen staining, AFB culture and/or clinical re-
sponse to treatment (along with fever, cough andweight loss).
All PTB patients had findings consistent with active TB as
evaluated by one of the consulting physicians. Twenty-two
patients had a positive AFB smear upon microscopy. Fourteen
patients had a negative AFB smear, but showed a favorable
clinical response to ATT. Patients were diagnosed as having
minimal, moderate or advanced pulmonary tuberculosis
using a modified classification of the National Tuberculosis
Association of the USA based on extent of lung tissue involve-
ment [21]. Of the PTB patients, 23 had moderately advanced,
while 13 had far advanced disease.
Diagnosis of TB lymphadenitis, spinal and abdominal TB
was based on histopathological findings of chronic granulom-
atous inflammation with caseous necrosis, AFB staining and
culture and supportive radiological evidence on CT or MRI.
Diagnosis ofmeningeal TBwas based onCSF biochemical find-
ings, supported by AFB culture and findings on contrast-en-
hanced CT and/or MRI. Pleural TB was diagnosed on the
basis of pleural fluid biochemical findings, AFB culture, histo-
pathological findings on pleural biopsy, and supportive radio-
logical evidence on X-rays and/or contrast-enhanced CT scan.
Patients with extrapulmonary TB (EPTB) were divided into
two groups according to the WHO case definitions of severity
of TB disease based on bacillary load, extent of disease and
anatomical site [22]. EPTB patients were subsequently classi-
fied into less severe (L-ETB) or severe disseminated (D-ETB)
disease. Therefore, the 31 ETB patients comprised those
which had limited ETB (L-ETB) comprising tuberculous
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(n = 12). Patients with disseminated extrapulmonary TB (D-
ETB) comprised those with spinal TB (N = 4), abdominal TB
(n = 2), miliary disease (N = 2), bilateral pleural effusions
(n = 1) or tuberculous meningitis (n = 1).
BCG-vaccinated asymptomatic healthy volunteers who
were staff at AKU with no known exposure to TB were used
as endemic controls (ECs). All volunteers had a normal chest
X-ray. All healthy endemic controls were BCG vaccinated.
Reagents
Recombinant antigen ESAT-6 from M. tuberculosis H37Rv was
provided through the TB Vaccine Testing and Research Mate-
rials Contract, NIH, NIAID NO1-A1-40091, awarded to Colo-
rado State University, USA.
Whole blood assay
Whole blood cultures were set up as described previously [23].
Cells were stimulated with recombinant antigens ESAT-6
(5 lg/ml) and cultured for 5 days and supernatants collected
at 2- and 5-day post-stimulation for cytokine and chemokine
measurements. All samples were set up in replicates. Sam-
ples were centrifuged to collect any cellular debris, aliquoted
and stored at 70 C until tested.
ELISA for IFN-c, CXCL9, CXCL10 and CCL2
IFN-c was detected in 5-day cellular supernatants by using
standards and ELISA reagents obtained from Endogen (Rock-
ford, IL, USA). IFN-c was measured using a sandwich ELISA
technique according to the manufacturer’s instructions and
as reported previously [17]. Recombinant human cytokine
was used to obtain a dose response curve with a range of
detection from 3.9–1000 pg/ml. CXCL9, CXCL10 and CCL2 were
measured in 2-day supernatants. Standards and monoclonal
antibody pairs for capture and detection were obtained from
R&D Systems (Abingdon, UK). All measurements were carried
out according to the manufacturer’s recommendations and as
described previously [17]. Recombinant human cytokine was
used to obtain a dose response curvewith a range of detectionTable 1 – Hematological characteristics of tuberculosis patients
Group EC PTB
N 33 36
Age (years) 30 24
Male, Female 17, 16 19, 17
ESR (mm/h) 7 56
Hb (g/dL) 13.2 11.4
TLC (10e9/L) 7 9.2
Lymphocytes (10e9/L) 2.3 1.7
Monocytes (10e8/L) 4.6 7.2
Neutrophils (10e9/L) 4 6.4
Values depict median data for each group. EC, healthy endemic controls;
or severe disseminated disease (D-ETB).
ESR, erythrocyte sedimentation rate; Hb, hemoglobin; TLC, total lympho
*Denotes significant difference (p < 0.05) as determined by Kruskal–Wallisfrom 6.25–500 pg/ml for CXCL9, 4.4–1000 pg/ml for CXCL10
and 6.25–1000 pg/ml for CCL2.
Statistical analysis
Non-parametric statistical analysis was performed using
Kruskal–Wallis and Mann–Whitney U tests, and Chi-Square
test analyses were run using the Statistical Package for Social
Sciences software (SPSS Version 17.0). Cytokine cut-off with
sensitivity and specificity of the assays were determined
using MEDCALC software version 11.4.
Results
Study subjects
The hematological parameters of study subjects are shown in
Table 1. Patients comprised those with pulmonary TB (PTB)
and extrapulmonary TB (EPTB). The age of patients and
healthy endemic controls (EC) was comparable and there
were no gender differences between patients with pulmonary
or extrapulmonary TB.
ESAT6-induced IFN-c, CXCL9, CXCL10 and CCL2 in TB
patients and ECs
ESAT6-induced cytokine responses in ex vivo whole blood
cultures were measured in patients with TB and in healthy
endemic controls. ESAT6-induced IFN-c responseswere found
to be positive in 32% of TB patients and 15% in EC (p = 0.048).
Measurement of ESAT6-induced chemokines illustrated that
in TB patients 42% had positive CXCL9 responses, 8% were
positive using CXCL10 and 23% had a positive CCL2 response.
As shown in Table 2, these did not differ from those in healthy
endemic controls. When IFN-c and CXCL9 were used together
(in that either IFN-c or CXCL9) was positive, rates went up to
53% in TB patients and 27% in EC. A Chi-squared test run
between IFN-c/CXCL9 responders in TB as compared with
EC, this difference was significantly different (p = 0.014) When
IFN-c and CXCL10 were used together, positivity rates were
33% in TB and 27% in EC, p = 0.53. When IFN-c and CCL2 were
used, positivity rates were 45% in TB and 52% in EC.and healthy endemic controls.
L-ETB D-ETB p-Value
31 10
27 32.5 0.055
12, 19 4, 6
42 41 0
11.5 11.8 0
8 7.7 0.017
1.9 1.8 0.004
5.5 5.8 0.057
5.2 5.2 0.005
PTB, pulmonary TB; extrapulmonary TB with limited disease (L-ETB)
cyte count.
analysis.
Table 2 – ESAT6-induced IFN-c in combination with chemokines to diagnose active TB.
Positive responders (%)a
IFNc p-Value CXCL9 p-Value CXCL10 p-Value CCL2 p-Value IFNc-CXCL9 p-Value IFNcCXCL10 p-Value
EC 15 15 15 39 27 27
TB 32 0.048 42 0.006 8 ns 23 ns 53 0.014 33 ns
PTB 31 ns 42 0.015 3 0.068 28 ns 53 0.031 31 ns
ETB 34 0.063 44 0.008 12 ns 20 ns 54 0.022 37 ns
L-ETB 39 0.033 42 0.017 16 ns 23 ns 55 0.088 42 ns
D-ETB 20 ns 50 0.022 0 ns 10 0 50 ns 20 ns
EC, healthy endemic controls; TB, tuberculosis patients; PTB, pulmonary TB; ETB, extrapulmonary TB; L-ETB, less severe extrapulmonary TB; D-
ETB, severe disseminated extrapulmonary TB.
Cut-off values were: IFNc > 0 pg/ml; CXCL9 29 pg/ml; CXCL10 23 pg/ml; CCL2 2256 pg/ml.
a A positive cut-off was based on MEDCALC software analysis, TB vs EC reference for each cytokine.
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uals with active TB in the population, it was not included in
further calculations.
Disease site-specific variation in the utility of ESAT6–induced
IFN-c, CXCL9 and CXCL10 responses
The number of positive responders that belonged to individu-
als with disease at different sites – pulmonary and extrapul-
monary TB – were further investigated. Patients were
stratified into PTB and EPTB patients comprising those with
limited (L-ETB) or severe disseminated (D-ETB) disease.
ESAT6-induced IFN-c, CXCL9 and CXCL10 responses in the
different individuals were compared with those of ECs.
ESAT6-induced IFN-c responses alone indicated 31%
responders in PTB, 39% in L-ETB and 20% in D-ETB groups, Ta-
ble 2. Using CXCL9 alone, 42% of PTB; 42% of L-ETB; and 50%
of D-ETB patients were found to be positive. Using CXCL10
alone, 3% of PTB, 16% of L-ETB but none in the D-ETB group
were positive. With IFN-c in combination with CXCL9, posi-
tive rates were 53% of PTB; 55% of L-ETB and 25% of D-ETB
as compared with EC 27%. In the case of IFN-c /CXCL10, posi-
tive rates were 31% of PTB; 42% of L-ETB and 20% of D-ETB as
compared with 27% in EC.
Overall, the highest number of positive ESAT6-induced
IFN-c and adjunct CXCL9 and CXCL10 responses were in L-
ETB, followed by PTB and D-ETB groups.Discussion
This study presents the diagnostic utility of ESAT6-induced
IFN-c and adjunct chemokine responses for detection of TB
in a highly endemic region in a low-HIV population. This data
shows that measurement of ESAT6-induced IFN-cwith CXCL9
increases the rate of detection of active tuberculosis. It was
observed that ESAT6-induced IFN-c and ESAT6-induced
CXCL9 responses were both significantly greater in TB pa-
tients as compared with healthy endemic controls.
Previously, studies in pediatric TB have reported CXCL10 to
be a better alternate marker for TB diagnosis [15]. Also, that
while CXCL10 alone was less effective than the Quantiferon
assay for detection of M. tuberculosis infection, measuring
both CXCL10 and IFN-c increased the number of TB patientsdetected [24]. It was not found that measuring CXCL10
increased the number of cases detected; however, this study’s
focus was on adults and results may differ from those studies
of children, who are more likely to have a greater innate and
less-effective adaptive immune response driven by T-cells
against Mycobacterium as compared with adults.
In a high transmission region, individuals are exposed at
increased rates to both environmental mycobacterial and M.
tuberculosis which results in modulation of antigen driven T-
cell IFN-c responses [25]. This data corresponds with Goletti
et al. which show a reduced diagnostic power of CXCL10 in
a setting with high TB endemicity owing to the increased
CXCL10 positive responses in those who did not have active
TB [26].
It was found that ESAT6-induced CCL2 did not discrimi-
nate between individuals with and without active TB and also
that this chemokine did not increase the number of detected
cases when used as an adjunct marker to IFN-c. These finding
are in contrast to findings by Ruhwald et al., in a study which
comprised 8 patients with pulmonary TB and 7 healthy ende-
mic controls [18]. However, the strength of the present study
was greater (33 controls and 67 TB patients) than that of the
former and thus may have more relevant information for an
endemic region.
Most notable amongst these results was that measure-
ment of CXCL9 with IFN-c increased the rate of active TB
detection in patients with both pulmonary and extrapulmo-
nary TB. This is especially pertinent for cases of extrapulmo-
nary TB which pose diagnostic dilemmas owing to difficulty
in obtaining site-specific specimens for microbiological tests.
In the cases of L-ETB, IFN-c alone was sufficient to diagnose
active TB; however, in D-ETB cases, CXCL9 measurement with
IFN-c increased the rates of active TB detected. This fits with
previous results which have shown that ESAT6-induced
CXCL9 responses are increased in patients with severe dis-
seminated TB, while IFN-c responses are reduced in the group
[19].Conclusion
This study reports the utility of the combined measurement
of IFN-c and CXCL9 for detection of TB. As early diagnosis of
extrapulmonary TB remains a challenge, a minimally invasive
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be very useful for diagnosis of active TB. However, given that
only 50% of all active TB cases were detected, these markers
should not be used in isolation and must be analyzed in con-
junction with clinical correlation and additional relevant
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